Main Menu

IP Litigators Ken Dorsney and Cortlan Hitch Contribute to New Book on Biosimilars Litigation

News & Media Mentions

June 11, 2024
Biosimilars Litigation and Client Counseling - Available through American Bar Association

Intellectual Property attorneys Kenneth Dorsney and Cortlan Hitch have edited and contributed to the newly published book Biosimilars Litigation and Client Counseling, which is available through the American Bar Association.

This comprehensive guide offers an in-depth exploration of the legal landscape surrounding biosimilars, a rapidly evolving area in the pharmaceutical industry. "Biosimilars Litigation and Client Counseling" is now available for purchase through the American Bar Association's online store. Legal professionals, industry stakeholders, and anyone interested in the future of biosimilars will find this book to be an invaluable resource.

Biosimilars, which are highly similar to FDA-approved biologic products, have introduced new challenges and opportunities in the field of intellectual property and patent litigation. As key contributors, Ken and Cortlan bring extensive experience in federal court litigation and expertise in navigating complex legal issues to this essential resource for legal practitioners and their clients. The book focuses on the strategic considerations and litigation tactics crucial for successfully handling biosimilar cases.

About Ken Dorsney

Ken Dorsney, the Chair of Morris James' Intellectual Property Practice, is a registered patent attorney with over 20 years of experience in resolving patent, trademark, trade secret, and copyright disputes. His practice focuses on representing corporate clients in a wide variety of complex commercial matters, including litigation, mediation, and dispute resolution in the District of Delaware.

About Cortlan Hitch

Cortlan Hitch also brings a wealth of experience to the table, with a strong focus on intellectual property litigation. His contributions to the book highlight his expertise in handling intricate legal challenges associated with biosimilars.

PDF
Back to Page